3 Things I bet you didn't know about....PharmAust

PharmAust is a clinical-stage company developing therapeutics for humans & animals. They specialise in repurposing marketed drugs, lowering the risks and costs of development.

1. They are absolute experts at ….

PharmAust is the absolute experts at helping treat dogs with aggressive lymphoma by developing a novel safe, effective, affordable oral treatment families can use at home.  

Phase 2 clinical trials of PharmAust’s Monepantel drug showed that at the optimum target level, 100% of dogs with treatment naïve B-cell lymphoma achieved stable disease  or better as assessed by the administering vets, and side effects were minimal. At the optimum level, MPL treatment also showed evidence of complete tumour regression.  

Repurposing an existing drug that is safe, approved and widely used, for new, targeted treatments for cancers and other serious diseases in animals and people. 

Monepantel is an established sheep drench, which an astute clinician noticed appeared to help reduce animal tumours.  

2. The one thing that makes them different from their competitors is....

Because PharmAust repurposes existing drugs with established safety and use data, we can develop and gain approval for new applications relatively quickly and cost effectively. 

Monepantel represents a potential step change in canine lymphoma treatment versus costly and lengthy existing CHOP chemotherapy, which has significant side effects.

PharmAust hypothesises Monepantel works through an autophagy mechanism, inhibiting the mTOR protein which controls cell survival, and therefore has broad potential application.

For example, PharmAust is working with research partners to explore Monepantel’s potential action on the cancer inducing HTLV-1 and COVID-19 respiratory viruses.

Phase 1 human trials of Monepantel to treat motor neuron disease, COVID-19 and a number of cancers are planned for 2022.  

3. They can make your life easier by ….

PhamAust is currently recruiting dogs across Australian trial sites focused on dose optimisation before commencing a Phase 3 trial for registration with a targeted approximate starting date of March 2022, prior to seeking to bring Monepantel to market. Site centres can be found at https://www.pharmaust.com/petdogtrial/ and for any further information, please contact Dr Richard Mollard, Chief Scientific Officer of PharmAust and Chief Executive Officer of PharmAust’s wholly owned subsidiary Pitney Pharmaceuticals Pty Ltd:

Email: rmollard@pharmaust.com

Tel: +61 418 367 855